Dendreon Receives FDA Acknowledgement of Complete Response
| 11/20/2009 | SEATTLE, Nov. 20 Dendreon Corporation (Nasdaq: DNDN ) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by... [Comments] |
Novavax Prices Public Offering of Common Stock
| 11/20/2009 | ROCKVILLE, Md., Nov. 20 Novavax, Inc. (Nasdaq: NVAX ) today announced that it has priced an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $3.30 per share. The approximately $21 million of net proceeds, after deducting the underwriting discounts and commissions, will be used for preclinical studies and cli... [Comments] |
Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
| 11/20/2009 | STOCKHOLM, November 20 Karolinska Development AB todayannounced that the European Investment Fund (EIF) has entered into aco-investment agreement with the company. The co-investment fund will bemanaged by Karolinska Development and used to invest in the company'sportfolio of early-stage pharmaceutical and medical technology companies. EIFhas agreed to inve... [Comments] |
Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
| 11/20/2009 | SEATTLE, Nov. 20 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that CTI should be allowed to pursue all of its claims against The Lash Group, sending the case back to the District Court for trial. CTI filed a complaint against The Lash Group, CTI... [Comments] |
Roller Compaction Process Optimization Using At-Line Particle Characterization
| 11/20/2009 | METTLER TOLEDO recently announced that a free webinar, “Roller Compactions Process Optimization Using At-Line Particle Characterization”, will be presented on December 2, 2009. In this webinar, the application of in situ particle characterization is demonstrated to map the design space and optimize a series of roller compaction runs while varying raw materi... [Comments] |
Process Analytical Technology (PAT) in Green Chemistry and Green Engineering
| 11/20/2009 | METTLER TOLEDO recently announced that Dr. Dominique Hebrault will present a free webinar, “The Role of Process Analytical Technology (PAT) in Green Chemistry and Green Engineering” on December 1, 2009. (PRWEB) November 20, 2009 -- D... [Comments] | ![]() |
Nanotube defects equal better energy and storage systems
| 11/19/2009 | Most people would like to be able to charge their cell phones and other personal electronics quickly and not too often. A recent discovery made by UC San Diego engineers could lead to carbon nanotube-based supercapacitors that could do just this. In recent research, published in Applied... [Comments] | ![]() |
DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel
| 11/19/2009 | COPENHAGEN, Nov. 19 Danish Prince Joachim inaugurated the DONG Energy and Inbicon cellulosic ethanol plant in Kalundborg, Denmark, on Wednesday, November 18. The facility is one of the world's first and largest 2nd generation ethanol demonstration biorefineries. Genencor's Accellerase enzymes are used in the plant's innovative process for converting straw to fuel. Genen... [Comments] |
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
| 11/19/2009 | SEATTLE, Nov. 19 Omeros Corporation (Nasdaq: OMER ) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended September 30, 2009, Omeros reported a net loss of $3.9 million, or $1.34 per share, as compared to a net loss of $7.4 million, or $2.54 per share, for the same period in 2008. For the nine... [Comments] |
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
| 11/19/2009 | BLAUVELT, N.Y., Nov. 19 Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences. Dr. Hidvegi stated from his office in Budapest, Hungary: "The Biropha... [Comments] |